Journal: Molecular cell

Article Title: The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2

doi: 10.1016/j.molcel.2018.12.001

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Human: CHL-1 , ATCC , CRL-9446.

Techniques: Western Blot, Transduction, In Situ, Virus, Recombinant, Lysis, Protease Inhibitor, Staining, Magnetic Beads, Cloning, Bicinchoninic Acid Protein Assay, Isolation, Labeling, Viability Assay, RNA Sequencing, Sequencing, Gene Expression, CRISPR, Mass Spectrometry, Expressing, Mutagenesis, shRNA, Plasmid Preparation, Control, Luciferase, Software, Membrane, Blocking Assay

Journal: Surgery

Article Title: Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy *

doi: 10.1016/j.surg.2019.04.067

Figure Lengend Snippet: Selected carcinogenesis-related differentially expressed lncRNAs between ACC and NAC

Article Snippet: The gene expression assays used were: HOTTIP (Hs03649396_m1), CHL1 (Hs04332026_m1), HOXA11-AS1 (Hs_03454334_g1), CRNDE (HS04404483_m1), LINC00271 (Hs03657384_m1), FAM211A-AS1 (Hs03678558_g1), TBXAS1 (Hs01096058_s1) and GAPDH (Hs99999905_m1).

Techniques:

Journal: Science translational medicine

Article Title: Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans.

doi: 10.1126/scitranslmed.aba6334

Figure Lengend Snippet: Fig. 2. Identifying alterations in CSF proteins in neuronal-selective Vps35 KO mice. (A) Listed proteins are those that are significantly reduced or elevated in the CSF of Vps35 cKO mice compared with controls. The four BACE1 substrates are indicated in red. (B) Scatterplots show the distribution of the four identified BACE1 substrates: APLP2, CHL1, APLP1, and APP. Values are reported as label-free quantification (LFQ) intensity and represent the mean of technical duplicates. Bars indicate the means ± SD; Limma-calculated q values are reported (n = 3 to 4 per genotype; ***q < 0.001 and **q < 0.05). (C) As illustrated, these substrates are cleaved at the endosomal membrane by BACE1, liberating N-terminal fragments into the endosomal lumen.

Article Snippet: The following six CHL1 antibodies were screened for compatibility: 8 = MABN229 (Millipore), 9 = AF2147 (Novus Biologicals), 11 = MAB2126 (Novus Biologicals), 12 = 25250-1-AP (ProteinTech), 13 = MAB2147 (Novus Biologicals), and 14 = LS-C485419 (LSBio) using membrane proximal extracellular domain CHL1 recombinant protein #AG19263 (ProteinTech) using Simoa homebrew kit (catalog no. 101354, Quanterix) and standard assay definitions.

Techniques: Quantitative Proteomics, Membrane

Journal: Science translational medicine

Article Title: Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans.

doi: 10.1126/scitranslmed.aba6334

Figure Lengend Snippet: Fig. 4. Validating BACE1 substrates and Tau accumulation in mouse CSF. (A) Immunoblotting with antibodies directed against the N-terminal fragments of APLP1 (n-APLP1) and CHL1 (n-CHL1) in the CSF of a mixed sex cohort of Vps35 cKO mice (red circles) versus controls (black circles) (n = 6 to 8 per genotype; *P < 0.05). Representative immunoblots are shown on the left. Data are shown as means ± SD (middle). Scatterplots showing the relationship between n-APLP1 and n-CHL1 in the CSF of Vps35 cKO mice (red circles) and controls (black circles) (n = 14, = 0.89, P < 0.0001; right). (B) Simoa assay was used to measure md-Tau in postmortem CSF in a mixed sex cohort of Vps35 cKO mice (red circles) versus controls (black circles) (n = 5 to 9 per genotype; P < 0.00001). Two-tailed unpaired Student’s t test was used for the statistical analysis (left). Antemortem CSF collected from females and males at 3 months (n = 11 to 13 per genotype, P < 0.0001) and 6 months (n = 8 to 10 per genotype, P < 0.0001) of age was analyzed using an md-Tau Simoa assay. A two-way ANOVA Sidak’s multiple comparisons test was used for the statistical analysis (right). Data are shown as means ± SD. (C) Representative Nissl staining analysis in the hippocampus of 3-month-old Vps35 cKO mice compared with their control littermates. n = 6 animals per genotype (P = 0.8182, in a nonparametric Mann-Whitney test). Hippo- campal CA1 region is shown at higher magnification. Scale bars, 200 m. (D) Western blot analysis of hippocampal tissue from 3-month-old Vps35 cKO and control littermates (control) showing expression of neurotubulin (P = 0.0001), presynaptic (PSD95, P = 0.8319), or postsynaptic (synaptophysin, P = 0.3558) markers. Data are shown as means ± SEM. n = 6 animals per genotype. Two-tailed unpaired Student’s t test was used for the statistical analysis (*P < 0.05). Significance is indicated as *P < 0.05, **P < 0.01, and ***P < 0.005.

Article Snippet: The following six CHL1 antibodies were screened for compatibility: 8 = MABN229 (Millipore), 9 = AF2147 (Novus Biologicals), 11 = MAB2126 (Novus Biologicals), 12 = 25250-1-AP (ProteinTech), 13 = MAB2147 (Novus Biologicals), and 14 = LS-C485419 (LSBio) using membrane proximal extracellular domain CHL1 recombinant protein #AG19263 (ProteinTech) using Simoa homebrew kit (catalog no. 101354, Quanterix) and standard assay definitions.

Techniques: Western Blot, Two Tailed Test, Staining, Control, MANN-WHITNEY, Expressing

Journal: Science translational medicine

Article Title: Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans.

doi: 10.1126/scitranslmed.aba6334

Figure Lengend Snippet: Fig. 5. The relationship of n-APLP1, n-CHL1, and md-Tau is selectively correlated in the CSF of patients with Alzheimer’s dementia. (A) Scatterplots showing the correlations between n-APLP1 and n-CHL1 (left; n = 316; = 0.72, P = 9.1 × 10−48), n-APLP1 and md-Tau (middle; n = 316; = 0.6, P = 1.3 × 10−30), and n-CHL1 and md-Tau (right; n = 316; = 0.53, P = 1.7 × 10−33) in the CSF of patients with mild to moderate AD. (B) Scatterplots showing the relationships in amyloid-negative (blue circles) and amyloid-positive (red circles) individuals.

Article Snippet: The following six CHL1 antibodies were screened for compatibility: 8 = MABN229 (Millipore), 9 = AF2147 (Novus Biologicals), 11 = MAB2126 (Novus Biologicals), 12 = 25250-1-AP (ProteinTech), 13 = MAB2147 (Novus Biologicals), and 14 = LS-C485419 (LSBio) using membrane proximal extracellular domain CHL1 recombinant protein #AG19263 (ProteinTech) using Simoa homebrew kit (catalog no. 101354, Quanterix) and standard assay definitions.

Techniques:

Journal: Science translational medicine

Article Title: Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans.

doi: 10.1126/scitranslmed.aba6334

Figure Lengend Snippet: Fig. 7. n-APLP1, n-CHL1, and md-Tau in the CSF of healthy controls and patients with prodromal AD. A set of 39 healthy controls and 19 prodromal AD classified on the basis of Tau/A42 cutoff for AD (≥0.15) were analyzed using the n-APLP1, n-CHL1, and md-Tau assays. Shown is an in-between group comparison analysis in the corrected concentrations of n-APLP1 (F = 84.2, P = 9.4 × 10−13) and n-CHL1 (F = 78.2, P = 3.2 × 10−12) in patients with prodromal AD versus healthy controls.

Article Snippet: The following six CHL1 antibodies were screened for compatibility: 8 = MABN229 (Millipore), 9 = AF2147 (Novus Biologicals), 11 = MAB2126 (Novus Biologicals), 12 = 25250-1-AP (ProteinTech), 13 = MAB2147 (Novus Biologicals), and 14 = LS-C485419 (LSBio) using membrane proximal extracellular domain CHL1 recombinant protein #AG19263 (ProteinTech) using Simoa homebrew kit (catalog no. 101354, Quanterix) and standard assay definitions.

Techniques: Comparison

Journal: Science translational medicine

Article Title: Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans.

doi: 10.1126/scitranslmed.aba6334

Figure Lengend Snippet: Fig. 6. The relationship of n-APLP1, n-CHL1, and md-Tau in the CSF of healthy controls and patients with MCI. (A) Scatterplots showing the relationship between n-APLP1 and n-CHL1 (top; n = 40; = 0.97, P = 2.4 × 10−24), n-APLP1 and md-Tau (middle; n = 40; = 0.86, P = 1.7 × 10−12), and n-CHL1 and md-Tau (bottom; n = 40; = 0.87, P = 2.1 × 10−17) in the CSF of healthy controls. (B) Scatterplot showing the relationship between n-APLP1 and n-CHL1 (top; n = 21; = 0.97, P = 6.5 × 10−13) in the CSF of patients with MCI. (C) Scatterplot showing relationships between n-APLP1 and n-CHL1 (top: healthy control, blue circles; MCIs, red circles) after adjustment for CSF A42. Scatterplot showing relationships between n-APLP1 and md-Tau (middle; n = 21; = 0.67, P = 0.001) and n-CHL1 and md-Tau (bottom; n = 21; = 0.79, P = 0.00002) after adjustment for CSF A42.

Article Snippet: The following six CHL1 antibodies were screened for compatibility: 8 = MABN229 (Millipore), 9 = AF2147 (Novus Biologicals), 11 = MAB2126 (Novus Biologicals), 12 = 25250-1-AP (ProteinTech), 13 = MAB2147 (Novus Biologicals), and 14 = LS-C485419 (LSBio) using membrane proximal extracellular domain CHL1 recombinant protein #AG19263 (ProteinTech) using Simoa homebrew kit (catalog no. 101354, Quanterix) and standard assay definitions.

Techniques: Control

Journal: Science translational medicine

Article Title: Tau and other proteins found in Alzheimer's disease spinal fluid are linked to retromer-mediated endosomal traffic in mice and humans.

doi: 10.1126/scitranslmed.aba6334

Figure Lengend Snippet: Fig. 8. n-APLP1 and n-CHL1 are correlated with phosphorylated Tau in the CSF of healthy controls and patients with AD. (A) Scatterplots showing the relationship between n-APLP1 and p-tau217 in the CSF of patients with mild to moderate AD (left; n = 316; = 0.36, P = 6.5 × 10−11), healthy controls (middle; n = 37; = 0.72, P = 5.1 × 10−7), and MCIs adjusted for CSF A42 (right; n = 21; = 0.63, P = 0.002). (B) Scatterplots showing relationship between n-CHL1 and p-tau217 in the CSF of patients with mild to mod- erate AD (left; n = 316; = 0.37, P = 6.4 × 10−11), healthy controls (middle; n = 37; = 0.62, P = 5.0 × 10−6), and MCIs adjusted for CSF A42 (right; n = 21; = 0.71, P = 0.0003).

Article Snippet: The following six CHL1 antibodies were screened for compatibility: 8 = MABN229 (Millipore), 9 = AF2147 (Novus Biologicals), 11 = MAB2126 (Novus Biologicals), 12 = 25250-1-AP (ProteinTech), 13 = MAB2147 (Novus Biologicals), and 14 = LS-C485419 (LSBio) using membrane proximal extracellular domain CHL1 recombinant protein #AG19263 (ProteinTech) using Simoa homebrew kit (catalog no. 101354, Quanterix) and standard assay definitions.

Techniques:

Journal: bioRxiv

Article Title: Bimolecule detection for Extracellular Vesicle Screening

doi: 10.1101/2020.07.23.217018

Figure Lengend Snippet: ( A ) Western blot analysis of CD63 EV marker in precipitated EV samples. The precipitated EVs derived using ExoQuick Solution were prepared from the serum collected from 2 mice of wild-type (WT) and EML4-ALK transgenic (TG) mouse as described in the “ Materials and methods ”. ( B ) Analysis of EMARS products obtained from EMARS reaction for crude mouse serum EVs. EMARS reaction was carried out directly in the precipitated serum EVs from two of WT and TG mice with or without HRP-conjugated CHL1 probe. The EMARS products were subsequently subjected to SDS-PAGE (10% gel) with fluorescein detection and CBB staining. ( C ) Fractionation using Sephacryl S-500 chromatography. Blue dextran (an indicator of void volume) and mouse serum (an indicator of protein elution) were used for preliminary experiments. The dotted line indicates absorbance of blue dextran. The solid line indicates protein concentration measured using a BCA protein kit. ( D ) Morphological observation of serum EVs (fraction No. 6 and No. 8) using cryo-electron microscopy. Lower panel of fraction No.6 is an enlarged view of a part of the upper panel. Scale bar; 200 nm (upper panel) and 50 nm (lower panel).

Article Snippet: In the case of the human CHL1 level in serum and serum EVs by sandwich ELISA, diluted serum or precipitated serum EVs described above were applied to the ELISA plates after coated with capture antibody, anti-human CHL1 antibody (10143-MM05; Sino Biological, Beijing, China), followed by the detection with HRP-conjugated anti-human CHL1 antibody (described above).

Techniques: Western Blot, Marker, Derivative Assay, Transgenic Assay, SDS Page, Staining, Fractionation, Chromatography, Protein Concentration, Electron Microscopy

Journal: bioRxiv

Article Title: Bimolecule detection for Extracellular Vesicle Screening

doi: 10.1101/2020.07.23.217018

Figure Lengend Snippet: ( A ) Protein expression of precipitated EVs. The serum collected from seven mice of wild-type (WT) and EML4-ALK transgenic mouse (TL group) was subjected to Western blot analysis with anti-CHL1, anti-α2 integrin, anti-β1 integrin, and anti-FGFR3 antibodies, which were cancer cell membrane BiCAT molecules previously reported. ( B ) Western blot analysis for TSG101 antigen detection in Sephacryl S-500 fractions. The fractions were concentrated with Nanosep ® centrifugal unit, and then subjected to Western blot analysis with anti-TSG101 antibody. TSG101-(Ub)n indicates ubiquitinated TSG101.

Article Snippet: In the case of the human CHL1 level in serum and serum EVs by sandwich ELISA, diluted serum or precipitated serum EVs described above were applied to the ELISA plates after coated with capture antibody, anti-human CHL1 antibody (10143-MM05; Sino Biological, Beijing, China), followed by the detection with HRP-conjugated anti-human CHL1 antibody (described above).

Techniques: Expressing, Transgenic Assay, Western Blot

Journal: bioRxiv

Article Title: Bimolecule detection for Extracellular Vesicle Screening

doi: 10.1101/2020.07.23.217018

Figure Lengend Snippet: ( A ) The EMARS products for serum EVs from EML4-ALK transgenic mouse. To average experimental results over each group, an aliquot of the serum (10 μL each) from 10 animals in each group (WT), large lung tumor-bearing (TL), and small lung tumor-bearing mice (TS) was mixed in equal proportions, and then applied to EV purification and EMARS. The EMARS products were concentrated and purified by immunoprecipitation with the anti-fluorescein antibody Sepharose. The resulting samples were subjected to SDS-PAGE analysis with fluorescence detection. “IP” indicates the immunoprecipitated samples, and “Lys” indicates the lysate samples before immunoprecipitation. The right panel indicates the same gel as the left panel, but exposed for a longer time. ( B ) Confirmation of candidate partner molecules (CD5L and PZP) with mouse CHL1 in EVs. The EMARS products of WT, TL, and TS were respectively applied to immunoprecipitation (anti-fluorescence antibody Sepharose) and western blot analysis with anti-CD5L (left panel) antibody. After the stripping as described in the “ Materials and methods ”, the membranes were re-stained with anti-PZP antibody (right panel). Arrows indicate the detected band of CD5L and PZP proteins (including predicted dimer). Asterisk indicates unknown bands (predicted as non-specific or partial fragments). ( C, D ) Confirmation of candidate partner molecules (SLC4A1 and THBS1) with mouse CHL1 in EVs. The western blot analysis was performed with anti-SLC4A1 antibody ( C ). After stripping, the membranes were re-stained with anti-THBS1 antibody ( D ). Arrows indicate the detected band of SLC4A1 and THBS1 proteins (including predicted dimers). Asterisks indicate unknown bands (predicted as non-specific or partial fragments). ( E ) Expression of SLC4A1 (left column) and CHL1 proteins (right column) in tumor tissues from two male and two female EML4-ALK transgenic mice. The fragments of lung cancer tissues were mashed and washed gently with PBS, and then lysed with SDS-PAGE sample buffer directly. The resulting samples were subjected to Western blot analysis with anti-SLC4A1 antibody and anti-CHL1 antibody. Arrows indicate the detected band of monomer SLC4A1 and CHL1 proteins.

Article Snippet: In the case of the human CHL1 level in serum and serum EVs by sandwich ELISA, diluted serum or precipitated serum EVs described above were applied to the ELISA plates after coated with capture antibody, anti-human CHL1 antibody (10143-MM05; Sino Biological, Beijing, China), followed by the detection with HRP-conjugated anti-human CHL1 antibody (described above).

Techniques: Transgenic Assay, Purification, Immunoprecipitation, SDS Page, Fluorescence, Western Blot, Stripping Membranes, Staining, Expressing

Journal: bioRxiv

Article Title: Bimolecule detection for Extracellular Vesicle Screening

doi: 10.1101/2020.07.23.217018

Figure Lengend Snippet: ( A, B ) Western blot analysis of TSG101 ( A ) and CD63 ( B ) in serum EVs from WT, TL, and TS using anti-TSG101 and CD63 antibody. Arrows indicate the detected band of monomer TSG101 and CD63. The black bar indicates wide range of molecular weight due to an ubiquitination in TSG101 (TSG101-(Ub)n). ( C ) Western blot analysis of EMARS products with anti-CHL1 antibody. The EMARS products were concentrated and purified by immunoprecipitation with the anti-fluorescein antibody Sepharose. The resulting samples were subjected to SDS-PAGE analysis with fluorescence detection. “IP” indicates the immunoprecipitated samples, and “Lys” indicates the lysate samples before immunoprecipitation. Arrow indicates the detected band of CHL1. Asterisk indicates unknown bands (predicted as non-specific or partial fragments).

Article Snippet: In the case of the human CHL1 level in serum and serum EVs by sandwich ELISA, diluted serum or precipitated serum EVs described above were applied to the ELISA plates after coated with capture antibody, anti-human CHL1 antibody (10143-MM05; Sino Biological, Beijing, China), followed by the detection with HRP-conjugated anti-human CHL1 antibody (described above).

Techniques: Western Blot, Molecular Weight, Purification, Immunoprecipitation, SDS Page, Fluorescence

Journal: bioRxiv

Article Title: Bimolecule detection for Extracellular Vesicle Screening

doi: 10.1101/2020.07.23.217018

Figure Lengend Snippet: ( A, B ) Calibration curve of sandwich ELISA for the detection of both SLC4A1 partial proteins and fluorescein-labeled SLC4A1. The detection of several concentrations of recombinant SLC4A1 partial protein using HRP-labeled anti-SLC4A1 antibody which is prepared using Zenon system is summarized in ( A ). The detection of several concentrations of self-made standard materials containing fluorescein-labeled SLC4A1 using HRP-labeled anti-fluorescein antibody is summarized in ( B ). ( C ) Comparison of serum CHL1 levels between wild-type (WT) and small tumor-bearing EML4-ALK transgenic (TS) mice by using previously established ELISA system for CHL1 measurement. There were no significant differences between them.

Article Snippet: In the case of the human CHL1 level in serum and serum EVs by sandwich ELISA, diluted serum or precipitated serum EVs described above were applied to the ELISA plates after coated with capture antibody, anti-human CHL1 antibody (10143-MM05; Sino Biological, Beijing, China), followed by the detection with HRP-conjugated anti-human CHL1 antibody (described above).

Techniques: Sandwich ELISA, Labeling, Recombinant, Transgenic Assay, Enzyme-linked Immunosorbent Assay

Journal: bioRxiv

Article Title: Bimolecule detection for Extracellular Vesicle Screening

doi: 10.1101/2020.07.23.217018

Figure Lengend Snippet: ( A ) Calibration curve of sandwich ELISA for the detection of both human CHL1. The detection of several concentrations of recombinant human CHL1 partial protein using HRP-labeled anti-CHL1 antibody. ( B ) Comparison of serum CHL1 levels between H (open bar) and LC (closed bar) by using ELISA system for human CHL1 measurement. There were no significant differences between them. ( C ) Comparison of CHL1-expressing EVs between H (open bar) and LC (closed bar). The serum EVs were purified by using ExoQuick Solution followed by ELISA measurement of CHL1 levels. There were also no significant differences between them.

Article Snippet: In the case of the human CHL1 level in serum and serum EVs by sandwich ELISA, diluted serum or precipitated serum EVs described above were applied to the ELISA plates after coated with capture antibody, anti-human CHL1 antibody (10143-MM05; Sino Biological, Beijing, China), followed by the detection with HRP-conjugated anti-human CHL1 antibody (described above).

Techniques: Sandwich ELISA, Recombinant, Labeling, Enzyme-linked Immunosorbent Assay, Expressing, Purification

Journal: bioRxiv

Article Title: Bimolecule detection for Extracellular Vesicle Screening

doi: 10.1101/2020.07.23.217018

Figure Lengend Snippet: ( A ) EMARS products purified from serum EVs of healthy person (H) and lung cancer (LC) patients. Fifty microliters of mouse serums was collected from the H and LC groups, and utilized in EV purification followed by EMARS reactions. To average experimental results over each group, an aliquot of the serum (10 μL each) from 5 H and 5 LC was mixed each in equal proportions. The EMARS products were subjected to SDS-PAGE analysis with fluorescence detection. ( B ) Confirmation of caspase 14 as a partner molecule with CHL1 identified by MS proteomics. The H and LC samples were applied respectively to immunoprecipitation (anti-fluorescence antibody Sepharose) and western blot analysis with anti-caspase 14 antibodies. Arrows indicate the detected band of caspase 14 proteins (including predicted dimer). ( C ) Measurement of fluorescein-labeled caspase 14 using a sandwich ELISA. Serum EVs from 12 H (open bar) and 12 LC (closed bar) were applied to EMARS reactions followed by ELISA measurements, respectively. The EMARS products containing fluorescein-labeled caspase 14 were added to anti-caspase 14 antibody-coated ELISA plates. “BiEV index (caspase 14)” was calculated based on the value of fluorescein-labeled recombinant caspase 14 made by fluorescein-labeling regent. The values are shown as the average of three independent ELISA experiments using the same samples. The detail data of H and LC persons is provided in Table S3. Asterisks indicate the samples were below detection limit. ( D ) ROC curve for BiEV indexes. The AUC was calculated as 0.811. ( E ) Western blot analysis of caspase 14 in whole-serum EVs from H and LC. An aliquot of the serum (2 μL each) from 12 persons in H and LC was mixed in equal proportions followed by EV purification with precipitation protocol. Arrows indicate the detected band of caspase 14.

Article Snippet: In the case of the human CHL1 level in serum and serum EVs by sandwich ELISA, diluted serum or precipitated serum EVs described above were applied to the ELISA plates after coated with capture antibody, anti-human CHL1 antibody (10143-MM05; Sino Biological, Beijing, China), followed by the detection with HRP-conjugated anti-human CHL1 antibody (described above).

Techniques: Purification, SDS Page, Fluorescence, Immunoprecipitation, Western Blot, Labeling, Sandwich ELISA, Enzyme-linked Immunosorbent Assay, Recombinant

Journal: PLoS ONE

Article Title: Genome wide profiling in oral squamous cell carcinoma identifies a four genetic marker signature of prognostic significance

doi: 10.1371/journal.pone.0174865

Figure Lengend Snippet: Concordance percentage for amplification of LRP12 (chr 8q), CCND1 (chr 11q), TPM2 (chr 9p), FSCN1 (chr 7p), EGFR (chr 7p), CLPTM1L (chr 5p) and deletion of CHL1 (chr 3p) and CSMD1 (chr 8p) identified using array CGH and validated using qPCR copy number analysis in OSCC samples.

Article Snippet: Copy number analysis was done on 66 OSCCs using TaqMan Copy Number Assay: LRP12 (Hs01987319_cn), FSCN1 (Hs03631914_cn), EGFR (Hs02309320_cn), CCND1 (Hs02226007_cn), CHL1 (Hs02163529_cn), TPM2 (Hs01060645_cn), CLPTM1L (Hs01133209_cn), CSMD1 (Hs03683117_cn) (Applied Biosystems, Foster City, CA, USA).

Techniques: Amplification

Journal: Oncotarget

Article Title: Expression and serum levels of the neural cell adhesion molecule L1-like protein (CHL1) in gastrointestinal stroma tumors (GIST) and its prognostic power

doi: 10.18632/oncotarget.27525

Figure Lengend Snippet: ( A ) Relative mRNA expression levels of pan CHL1, and isoforms 1 and 2 in primary GIST, ( B ) Western blot analyses of CHL1 protein expression in primary tumors and metastases.

Article Snippet: A polyclonal antibody raised against the extracellular domain of human CHL1 (CHL1/L1CAM-2 (AF2126; R&D Systems, USA) was used.

Techniques: Expressing, Western Blot

Journal: Oncotarget

Article Title: Expression and serum levels of the neural cell adhesion molecule L1-like protein (CHL1) in gastrointestinal stroma tumors (GIST) and its prognostic power

doi: 10.18632/oncotarget.27525

Figure Lengend Snippet: ( A ) Recurrence free survival for local CHL1 expression, ( B ) Overall survival for local CHL1 expression, ( C ) Recurrence free survival for serum CHL1 levels with cut-off values at 11.0 ng/ml, ( D ) Overall survival for serum CHL1 levels with cut-off values at 11.0 ng/ml, ( E ) Recurrence free survival for serum CHL1 levels with cut-off values at 14.5 ng/ml, ( F ) Overall survival for serum CHL1 levels with cut-off values at 14.5 ng/ml.

Article Snippet: A polyclonal antibody raised against the extracellular domain of human CHL1 (CHL1/L1CAM-2 (AF2126; R&D Systems, USA) was used.

Techniques: Expressing

Journal: Oncotarget

Article Title: Expression and serum levels of the neural cell adhesion molecule L1-like protein (CHL1) in gastrointestinal stroma tumors (GIST) and its prognostic power

doi: 10.18632/oncotarget.27525

Figure Lengend Snippet: Association of clinicopathological characteristics of GIST patients with local CHL1 expression and serum CHL1 levels (cut-off 11.0 ng/ml)

Article Snippet: A polyclonal antibody raised against the extracellular domain of human CHL1 (CHL1/L1CAM-2 (AF2126; R&D Systems, USA) was used.

Techniques: Expressing

Journal: Oncotarget

Article Title: Expression and serum levels of the neural cell adhesion molecule L1-like protein (CHL1) in gastrointestinal stroma tumors (GIST) and its prognostic power

doi: 10.18632/oncotarget.27525

Figure Lengend Snippet: Serum CHL1 levels in GIST ( A ) Serum CHL1 levels of patients with GIST and healthy controls. ( B ) Receiver operating characteristic (ROC) curves of serum CHL1 levels for detecting GIST.

Article Snippet: A polyclonal antibody raised against the extracellular domain of human CHL1 (CHL1/L1CAM-2 (AF2126; R&D Systems, USA) was used.

Techniques:

Journal: Oncotarget

Article Title: Expression and serum levels of the neural cell adhesion molecule L1-like protein (CHL1) in gastrointestinal stroma tumors (GIST) and its prognostic power

doi: 10.18632/oncotarget.27525

Figure Lengend Snippet: Prognostic value of serum CHL1 levels for recurrence free survival

Article Snippet: A polyclonal antibody raised against the extracellular domain of human CHL1 (CHL1/L1CAM-2 (AF2126; R&D Systems, USA) was used.

Techniques:

Journal: Journal of Inflammation Research

Article Title: Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology

doi: 10.2147/JIR.S444280

Figure Lengend Snippet: The Up-Regulated and Down-Regulated Top 5 Proteins Between the Two Groups

Article Snippet: Neural cell adhesion molecule L1-like protein (CHL1) kits (Cat: IHUUCHL1KT) and leukotriene A-4 hydrolase (LTA4H) ELISA kits (Cat: IHULTA4HKT) were provided by Innov Research (Michigan, USA).

Techniques:

Journal: Journal of Inflammation Research

Article Title: Serum Proteomic Analysis Revealed Biomarkers for Eosinophilic Chronic Rhinosinusitis with Nasal Polyps Pathophysiology

doi: 10.2147/JIR.S444280

Figure Lengend Snippet: Validation of the top 5 up and down-regulated proteins in an independent validation cohort. ( A – E ) comparison of serum MRC1, CDH13, LTA4H, CD5L and MMP2 concentrations between the eCRSwNP and neCRSwNP groups. ( F – J ) comparison of serum SERPING1, IGFBP5, TRIM28, CHL1 and FABP5 levels between the eCRSwNP and neCRSwNP groups. *P<0.05; **P<0.01; ***P<0.001.

Article Snippet: Neural cell adhesion molecule L1-like protein (CHL1) kits (Cat: IHUUCHL1KT) and leukotriene A-4 hydrolase (LTA4H) ELISA kits (Cat: IHULTA4HKT) were provided by Innov Research (Michigan, USA).

Techniques: Comparison